Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
InnoCan PharmaFRA:IP40 +1.05%58 Cash-to-Debt is 3.87 as of Jun. 2026, which is 98% below its 10-year median of 165.78. GuruFocus rates FRA:IP40 with a GF Score™ of 58/100 and a GF Value™ of €7.11 (Possible Value Trap). The stock has 2 warning signs investors should review. Among 1,947 Consumer Packaged Goods companies, InnoCan Pharma ranks better than 76.43% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. InnoCan Pharma's cash to debt ratio for the quarter that ended in Jun. 2026 was 3.87.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, InnoCan Pharmacould pay off its debt using the cash in hand for the quarter that ended in Jun. 2026.
The historical rank and industry rank for InnoCan Pharma's Cash-to-Debt or its related term are showing as below:
FRA:IP40'
s Cash-to-Debt Range Over the Past 10 Years
Min: 3.85 Med: 165.78 Max: No Debt
Current: 3.85
During the past 8 years, InnoCan Pharma's highest Cash to Debt Ratio was No Debt. The lowest was 3.85. And the median was 165.78.
FRA:IP40's Cash-to-Debt is ranked better than 76.43% of 1947
companies
in the Consumer Packaged Goods industry
Industry Median: 0.51
vs FRA:IP40: 3.85
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
InnoCan Pharma Cash-to-Debt Related Terms
InnoCan Pharma Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for InnoCan Pharma's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Household & Personal Products subindustry, InnoCan Pharma's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
InnoCan Pharma Cash-to-Debt vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, InnoCan Pharma's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where InnoCan Pharma's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
InnoCan Pharma (FRA:IP40) has a Cash-to-Debt of 3.87 as of Jun. 2026. This is 98% below median its historical median of 165.78. Over the past decade, InnoCan Pharma's Cash-to-Debt has ranged from 3.85 to 10,000.00. According to the industry distribution chart, InnoCan Pharma ranks #459 out of 1947 companies in the Consumer Packaged Goods industry, placing it in the top 23.6%.
Is InnoCan Pharma's Cash-to-Debt too high?
InnoCan Pharma's current Cash-to-Debt of 3.87 is 98% below median its 10-year median of 165.78. Over the past 10 years, this metric has ranged from a low of 3.85 to a high of 10,000.00. The Consumer Packaged Goods industry median Cash-to-Debt is 0.51. InnoCan Pharma's value of 3.87 is 658.8% above this industry median. Based on the distribution chart, InnoCan Pharma ranks #459 out of 1947 companies in the Consumer Packaged Goods industry, which is in the top quartile — a strong position relative to peers. Overall, InnoCan Pharma has a GF Score™ of 58/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does InnoCan Pharma's Cash-to-Debt compare to PG and CL?
According to the Consumer Packaged Goods industry distribution chart, InnoCan Pharma ranks #459 out of 1947 companies for Cash-to-Debt. This places InnoCan Pharma in the top 24% of its industry — outperforming the majority of peers. The industry median Cash-to-Debt is 0.51. InnoCan Pharma's value of 3.87 is 658.8% above this benchmark. Historically, InnoCan Pharma's own Cash-to-Debt has ranged from 3.85 to 10,000.00 over the past decade. While the company's 10-year median is 165.78 vs. the industry median of 0.51, InnoCan Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Consumer Packaged Goods company?
The median Cash-to-Debt among Consumer Packaged Goods companies is 0.51, based on 1,947 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. InnoCan Pharma's current Cash-to-Debt of 3.87 is 658.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Consumer Packaged Goods industry, the median Cash-to-Debt is 0.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. InnoCan Pharma's current Cash-to-Debt is 3.87, which is 98% below median its own 10-year median of 165.78. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is InnoCan Pharma stock overvalued right now?
Based on GuruFocus' analysis, InnoCan Pharma (FRA:IP40) is currently considered Possible Value Trap. The stock's GF Value™ is €7.11, compared to a current price of €1.43 — trading 79.9% below its estimated fair value. The current Cash-to-Debt is 3.87, which is 98% below median its 10-year median of 165.78 and 658.8% above the Consumer Packaged Goods industry median of 0.51. InnoCan Pharma's overall GF Score™ is 58/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For InnoCan Pharma (FRA:IP40), the current Cash-to-Debt is 3.87 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is InnoCan Pharma (FRA:IP40) Overvalued in 2026?
Based on GuruFocus' analysis, InnoCan Pharma stock appears to be undervalued.
The current stock price of €1.43 is trading 79.9% below its estimated GF Value™ of €7.11.
GuruFocus considers InnoCan Pharma to be Possible Value Trap.
Key valuation signals for FRA:IP40:
Cash-to-Debt: 3.87 (98% below median its 10-year median of 165.78)
GF Value™: €7.11 vs. price of €1.43 (79.9% below fair value)
Industry Position: 658.8% above the Consumer Packaged Goods median (#459 of 1947)
No single metric tells the full story. See the FRA:IP40 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
InnoCan Pharma Corp develops consumer wellness and pharmaceutical products. It has developed a preclinical-stage Cannabidiol-loaded Liposome injection Platform (CBD-LPT) for non-opioid pain management, and is involved in developing and marketing various self-care and CBD beauty products. Additionally, the Group offers cosmetic products such as anti-aging beauty sleeping masks, anti-puffiness eye serum, anti-aging facial serum, hair cream, etc., which are sold mainly through online marketplaces. Its operating segments are: Online sales and Other operations. The majority of its revenue is generated from the Online sales segment, which engages in the development, manufacture, and marketing of cosmetic products. Geographically, the Group generates maximum revenue from the United States.
58GF Score
Get the complete analysis for FRA:IP40
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:IP40 has been successfully added to your 
